- Home
- CUBI vs HCM Comparison
CUBI vs HCM Comparison
Compare CUBI & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- HCM
- Stock Information
- Founded
- CUBI 1994
- HCM 2000
- Country
- CUBI United States
- HCM Hong Kong
- Employees
- CUBI N/A
- HCM N/A
- Industry
- CUBI Major Banks
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- CUBI Finance
- HCM Health Care
- Exchange
- CUBI Nasdaq
- HCM Nasdaq
- Market Cap
- CUBI 2.3B
- HCM 2.6B
- IPO Year
- CUBI 2012
- HCM N/A
- Fundamental
- Price
- CUBI $66.96
- HCM $17.54
- Analyst Decision
- CUBI Buy
- HCM
- Analyst Count
- CUBI 8
- HCM 0
- Target Price
- CUBI $69.88
- HCM N/A
- AVG Volume (30 Days)
- CUBI 369.1K
- HCM 55.4K
- Earning Date
- CUBI 10-30-2025
- HCM 08-07-2025
- Dividend Yield
- CUBI N/A
- HCM N/A
- EPS Growth
- CUBI N/A
- HCM N/A
- EPS
- CUBI 4.05
- HCM 0.53
- Revenue
- CUBI $596,459,000.00
- HCM $602,197,000.00
- Revenue This Year
- CUBI $16.04
- HCM $2.73
- Revenue Next Year
- CUBI $6.11
- HCM $17.33
- P/E Ratio
- CUBI $16.54
- HCM $6.26
- Revenue Growth
- CUBI N/A
- HCM N/A
- 52 Week Low
- CUBI $40.75
- HCM $11.51
- 52 Week High
- CUBI $72.51
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- CUBI 48.16
- HCM 61.45
- Support Level
- CUBI $66.88
- HCM $15.51
- Resistance Level
- CUBI $69.05
- HCM $18.30
- Average True Range (ATR)
- CUBI 1.59
- HCM 0.33
- MACD
- CUBI -0.56
- HCM 0.28
- Stochastic Oscillator
- CUBI 10.19
- HCM 78.95
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.